SA PRO
Free Account
Collegium Pharmaceutical, Inc.COLLNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating
Buy
12 analysts·Moderate coverage
67%
Rating Distribution
Strong Buy
00%
Buy
867%
Hold
325%
Sell
18%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 19% higher.

Bear Case
$55.00
+15%
Consensus
$57.00
+19%
Bull Case
$60.00
+25%
Price Range12 analysts
Low
Consensus
High
$55.00
$60.00
Current Target
Current Price
$47.82
Upside to Target
$9.18

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 9, 2026Barclays
Collegium price target lowered to $56 from $58 at Barclays
Target:$56.00
+14.8%from $48.78
Jan 9, 2026H.C. Wainwright
Collegium Pharmaceutical price target raised to $60 from $46 at H.C. Wainwright
Target:$60.00
+23.0%from $48.78
Jan 7, 2026Truist Financial
Collegium Pharmaceutical price target raised to $55 from $47 at Truist
Target:$55.00
+19.0%from $46.21
Dec 8, 2025Barclays
Collegium Pharmaceutical initiated with an Overweight at Barclays
Target:$58.00
+21.1%from $47.91
Feb 4, 2025Piper Sandler
Collegium Pharmaceutical price target lowered to $36 from $37 at Piper Sandler
Target:$36.00
+16.4%from $30.93
Nov 11, 2024Jefferies
Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies
Target:$40.00
+24.3%from $32.18
Sep 4, 2024H.C. Wainwright
Collegium Pharmaceutical price target raised to $50 from $47 at H.C. Wainwright
Target:$50.00
+29.4%from $38.65
Aug 9, 2024Piper Sandler
Collegium Pharmaceutical (COLL) PT Lowered to $37 at Piper Sandler
Target:$37.00
+6.9%from $34.63
Jul 30, 2024H.C. Wainwright
H.C. Wainwright Upgrades Collegium Pharmaceutical (COLL) to Buy
Target:$47.00
+21.8%from $38.60
Jun 7, 2024Jefferies
Jefferies Upgrades Collegium Pharmaceutical (COLL) to Buy
Target:$44.00
+40.3%from $31.36
May 10, 2024Piper Sandler
Piper Sandler Downgrades Collegium Pharmaceutical (COLL) to Neutral on Valuation
Target:$39.00
+17.8%from $33.11
Jan 5, 2023Needham
Needham Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $35
Target:$35.00
+29.7%from $26.98

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance